Lupin licenses two oncology programmes to Kaveri Therapeutics for an 82.2% equity stake

The spin-out creates a dedicated US oncology company to raise capital and advance Lupin’s PRMT5 and SOS1 programmes through global clinical development.

Lupin has granted Kaveri Therapeutics exclusive, perpetual licences to two clinical-stage oncology programmes—LNP7457 and LNP8701—in exchange for an 82.2% equity stake, with the assets valued at $1.6 million.

The arrangement is intended to accelerate their development through an independently managed oncology company that will seek external funding for global clinical trials.

Field	Content
Alert Type	Deal
Companies	Lupin Inc., the wholly owned US subsidiary of Lupin Limited, and Kaveri Therapeutics
Deal Type	Strategic spin-out and exclusive perpetual licensing agreement involving an 82.2% equity stake
Asset or Company	LNP7457, a PRMT5-targeting programme, and LNP8701, a SOS1-targeting programme
Therapy Area(s)	Oncology
Technology or Modality	Targeted small-molecule oncology therapies
Deal Value	The two licensed programmes were valued at $1.6 million. Lupin received 332,000 common shares representing an 82.2% stake in Kaveri and will also provide seed funding, the amount of which was not disclosed.
Development Stage	Clinical-stage programmes in early clinical development
Geography	US-based transaction with planned global clinical development
What Happened	Lupin granted Kaveri exclusive, perpetual licences to LNP7457 and LNP8701 in exchange for an 82.2% equity stake. The transaction was completed on 20 July 2026, and Kaveri will assume responsibility for advancing the programmes through global clinical trials.
Background	Kaveri was incorporated in Delaware in May 2026 as a clinical-stage oncology company focused on solid tumours, including lung, pancreatic, ovarian and CNS-related cancers. Lupin reported that LNP7457 and LNP8701 presented positive clinical data at the 2025 and 2026 ASCO meetings, respectively.
Strategic Rationale	The structure places the two programmes within a dedicated, independently managed oncology company that can raise external capital and focus on global clinical development, while Lupin retains a majority equity interest in their future progress.
Why It Matters	The deal gives the programmes a specialised development vehicle and access to additional financing without Lupin relinquishing its majority economic interest. It also expands Kaveri’s pipeline across two targeted mechanisms relevant to difficult-to-treat solid tumours.
Potential Impact	Successful fundraising could support broader global trials and biomarker-driven development of the PRMT5 and SOS1 programmes, although their eventual clinical and commercial value will depend on future trial results.
Key Takeaway	Lupin is using a majority-owned spin-out to pursue external funding and focused clinical development for two targeted oncology assets.
What to Watch	Kaveri’s planned capital raise, the design and progression of global clinical trials, future data from both programmes and any additional financing or partnership arrangements.
Source Link	Lupin regulatory filing and accompanying company press release
Deal Date	21 July 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com